GlassScriptPhysician profile
Arielle Amanda Dahlin
NPI 1154827624
$1,569.53
in general payments reported to CMS, 2019-2025
21 companies · $476 in 2025
The $476 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $77.29 · 2022: $46.49 · 2023: $352 · 2024: $617 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,437 · Education: $8.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,437.21 |
| Education | $8.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $221.91 | 2024-2025 | Evenity, Repatha, Otezla |
| Astellas Pharma US INC | $191.41 | 2024-2025 | Veozah |
| Pfizer INC. | $165.74 | 2022-2025 | |
| Glaxosmithkline, LLC. | $155.96 | 2023-2025 | Trelegy Ellipta |
| Idorsia Pharmaceuticals US INC | $130.61 | 2023 | Quviviq |
| Abbvie INC. | $105.35 | 2021-2024 | Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $100.51 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Medtronic, INC. | $64.79 | 2025 | Symplicity G3, Minimed 780g |
| Dexcom, INC. | $60.93 | 2023-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $60.89 | 2021 | |
| Lilly USA, LLC | $47.02 | 2023-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $41.54 | 2025 | |
| Radius Health, INC. | $39.94 | 2024 | Tymlos |
| Merck Sharp & Dohme LLC | $34.80 | 2022 | |
| Novo Nordisk INC | $30.77 | 2023-2024 | Ozempic, Rybelsus |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $28.40 | 2025 | Flucelvax |
| Phathom Pharmaceuticals, INC. | $21.45 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.00 | 2024 | Xifaxan, Trulance |
| Xeris Pharmaceuticals, INC. | $18.00 | 2024 | Gvoke Hypopen |
| Corcept Therapeutics | $14.77 | 2025 | Korlym |
| Abbott Laboratories | $13.74 | 2024 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arielle Dahlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.